Weight Loss

Weight loss injections have had quite a lot of attention over the past few years. Now, the tablets would also like a moment.

Foundayo and Wegovy tablets are both once-daily GLP-1 medicines authorised in the UK for weight management. They work in similar ways, but they are not the same treatment in different packaging.

They contain different active ingredients, follow different dosing schedules and, perhaps most importantly for your morning routine, have very different instructions around food and drink.

Let's make the differences a little easier to swallow.

First Things First: What Are Foundayo and Wegovy Tablets?

Foundayo is the brand name for orforglipron, a daily GLP-1 tablet developed by Eli Lilly. Wegovy tablets contain semaglutide and are made by Novo Nordisk.

Both medicines act on GLP-1 receptors involved in appetite. They may help you feel fuller for longer, experience less hunger and manage food cravings, which can make a reduced-calorie diet feel more achievable.

Both are prescription-only

When a new weight-loss tablet arrives, it is reasonable to wonder what it is actually doing.

Does it burn fat? Speed up your metabolism? Make salad suddenly more appealing than fish and chips?

Not quite.

Foundayo, also known by its active ingredient orforglipron, is designed to help manage appetite. In simpler terms, it may make hunger feel a little less demanding.

Here is how it works.

What Is Foundayo?

Foundayo is a prescription-only GLP-1 medicine developed by Eli Lilly. In August 2026, it became the first oral GLP-1 treatment to be authorised in the UK for both weight management and type 2 diabetes.

Unlike GLP-1 treatments supplied as injections, Foundayo is taken as a tablet once a day. It can be taken at any time of day, without restrictions around food or water.

For weight management, it is authorised alongside a reduced-calorie diet and increased physical activity for adults with:

• A BMI of 30 or above; or
• A BMI between 27 and 30, plus at least one weight-related health condition.

Foundayo and Mounjaro come from the same pharmaceutical family, but they have taken very different approaches to getting into your system. One arrives as a daily tablet while the other prefers a weekly injection and brings its own pen.

Both are prescription-only treatments that can support weight management, but they contain different active ingredients, work on different hormone receptors and follow different dosing schedules.

So, what is the actual difference between them, and does one suit you better?

What Are Foundayo and Mounjaro?

Foundayo is the brand name for orforglipron. It is a once-daily GLP-1 tablet authorised in the UK for weight management and insufficiently controlled type 2 diabetes. Mounjaro contains tirzepatide. It is supplied as a pre-filled KwikPen and injected under the skin once a week. It is also authorised in the UK for weight management and type 2 diabetes.

Both treatments influence appetite, helping you feel fuller, reducing hunger and potentially making food cravings

When the scales start moving in the right direction, it is tempting to treat every lost kilogram as good news. After all, that is what you're using the medication for.

Weight, however, is not made up of just one single part.

When you lose weight, your body may lose fat, water and some lean tissue. That means the more useful question is not simply, "Am I losing weight?" it's more along the lines of: "What kind of weight am I losing?"

A Quick Reminder: What Is Foundayo?

Foundayo is the brand name for orforglipron, a prescription-only GLP-1 medicine developed by Eli Lilly. It was authorised in the UK in August 2026 for weight management and insufficiently controlled type 2 diabetes.

The tablet is taken once daily and works on areas of the brain involved in appetite. It may help you feel fuller, experience less hunger and manage food cravings, making a reduced-calorie diet easier to follow.

That can support weight loss. However, the body does not always take all its lost weight neatly from

If you are considering a weight-loss treatment, there is usually one question waiting at the front of the queue:

How much weight will I actually lose? It is an understandable question. It is also one without a guaranteed personal answer.

Clinical studies can tell us what happened on average across a large group of people. They cannot look into the future, inspect your bathroom scales and provide an exact number.

Here is what the research tells us and what it does not.

A Quick Introduction to Foundayo

Foundayo is the brand name for orforglipron, a prescription-only GLP-1 medicine developed by Eli Lilly. It was authorised in the UK in August 2026 for weight management and insufficiently controlled type 2 diabetes.

Unlike several existing GLP-1 treatments, Foundayo is taken as a once-daily tablet rather than an injection. It works by activating GLP-1 receptors involved in appetite. This can help you feel fuller, reduce hunger and manage food cravings, potentially making a reduced-calorie

You've been losing weight, amazing! That was exactly what you signed up for, and you probably weren't expecting much else beyond that.

You may have prepared yourself for some of the more familiar digestive side effects, such as diarrhoea or constipation. But what if you've started finding more hair than usual in the shower after hair-wash day?

Does Foundayo Truly Cause Hair Loss?

In short, yes. Hair loss is listed as a common side effect in the UK Foundayo Patient Information Leaflet, meaning it may affect up to 1 in 10 people.

Try not to worry. Just because the leaflet says, "up to 1 in 10", this does not make hair loss a definite outcome. Let's break down why it may happen and what you can do to support your hair while losing weight.

Why Might Weight Loss Affect Your Hair?

Think of your body like a bank account and food as the money coming in. When your food intake starts to decrease, your body has less to put towards all the different things it normally does.

The body does not consider

As a pharmacist, one of the first questions I get asked about the oral Wegovy pill is whether a needle-free option means paying more than the weekly injection. It is a sensible thing to ask, particularly when you're comparing a newer treatment option with an established one.

The short answer is: it depends on the dose and provider. The tablet may cost more at some stages of treatment, while the injection can become more expensive at higher strengths. That means the format itself doesn't tell you which option will cost less overall.

In this guide, I'll explain what affects Wegovy pricing, what additional costs to look for and why comparing the total cost of treatment is more useful than comparing a headline starting price.

Is the Wegovy Pill More Expensive Than the Injection?

It depends on the dose and provider you're comparing, not the format itself. UK pharmacies price the tablet against the injection quite differently, so there's no single answer that holds everywhere.

Where a gap does

Weight management has acquired quite a collection of injections over the past few years. Now, there is a new tablet at the table.

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Foundayo, also known as orforglipron, for weight management and type 2 diabetes in the UK. This makes the UK the first country in Europe to approve this particular GLP-1 tablet.

For anyone whose relationship with needles is best described as "not ideal", that may sound like significant news. However, approval does not mean Foundayo is suitable for everyone or immediately available through the NHS.

Here is what the announcement actually means.

What is Foundayo?

Foundayo is the brand name for orforglipron, a prescription-only GLP-1 receptor agonist made by Eli Lilly. Unlike injectable GLP-1 treatments, it is taken as a tablet once a day. It has been authorised for weight loss and weight maintenance in eligible adults, alongside a reduced-calorie diet and increased physical activity. It

As a pharmacist, I've lost count of how many times I've been asked this since the MHRA licensed the UK's first weight loss tablet, the oral Wegovy pill. It's a fair question, given how quickly this area of medicine is moving. I want to talk you through what the evidence tells us, why I don't think injections are about to disappear, and the questions I'd encourage any patient to think about before deciding which option might suit them best.

Are Weight Loss Pills as Effective as Injections?

When I look at the trial data, the difference appears relatively small for most people, although it isn't necessarily zero. Clinical trial data submitted to regulators in the UK and internationally suggests that oral semaglutide, the active ingredient in the Wegovy pill, produces weight loss broadly comparable to injectable semaglutide over similar treatment periods.

I'd also flag that some injectable medicines, particularly those that act on more than one appetite-related hormone, have shown somewhat

Hardly a week goes by without someone asking me about a new weight loss medicine. Over the past couple of years, I've watched the conversation around weight loss treatment change faster than at any other point in my career. Several pharmaceutical companies, including Novo Nordisk, Eli Lilly and Pfizer, are investing heavily in new treatments, and the UK now has its first MHRA-approved oral GLP-1 medicine licensed specifically for weight management: the oral Wegovy pill. I want to explain, in plain terms, why this field has become so competitive, what has actually changed here in the UK, and what I think is worth considering if you are weighing up whether treatment might be right for you. This is general information from my professional perspective, not personal medical advice, so please still speak to your own prescriber before making any decisions.

Why Has Weight Loss Become Such a Priority for Pharmaceutical Companies?

From what I see every day, it really comes down to scale. Obesity